


Synthesis of a Versatile (S)-3-(Hydroxymethyl)butane-1,2,4-triol Building Block and its Application for the Stereoselective Synthesis of N-Homoceramides

Ulrik Hillaert and Serge Van Calenbergh*

Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences,
Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium
serge.vancalenbergh@UGent.be

Received September 26, 2005

ABSTRACT



A versatile (S)-3-(hydroxymethyl)butane-1,2,4-triol building block has been synthesized starting from D-isoascorbic acid, a common food preservative. The key transformation in this approach was the introduction of branching through a high yield and fully regioselective epoxide opening. This flexible synthon has been elaborated to a new class of (dihydro-)N-homo(phyto)ceramides.

The development and availability of reliable and efficient methods for the construction of chiral building blocks are crucial for the synthesis of many pharmaceutical agents and complex natural products. These chiral building blocks can be derived from the chiral pool or by chemical/enzymatic means from achiral or racemic starting material.

(S)-3-(Hydroxymethyl)butane-1,2,4-triol is a flexible, multivalent, scaffold with defined stereochemical features which can be exploited by judicious selection of appropriate protecting groups. Some examples of the synthetic potential of this intermediate are summarized in Figure 1. Indeed, sugar derivatives (S,S)-4-(hydroxymethyl)pyrrolidine-3-ol,¹ the enantiomer of the common precursor of second-generation purine

phosphorylase inhibitors² and oxetanocin A, a known anti-bacterial, antitumoral, and antiviral natural product,³ are readily accessible through a limited number of steps (A). Moreover, ceramide analogues with an inversed amide functionality (B) could provide useful biochemical tools for assessment of ceramide interaction with a myriad of clinically relevant enzymes. Finally, simple elaboration of the other primary alcohol (C4–OH) to the amide part (C) gives access to

(2) (a) Kotian, P. L.; Chand, P. *Tetrahedron Lett.* **2005**, *46*, 3327–3330. (b) Makino, K.; Ichikawa, Y. *Tetrahedron Lett.* **1998**, *39*, 8245–8248. (c) Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; Tyler, P. C. *J. Med. Chem.* **2003**, *46*, 5271–5276.

(3) Selected examples: (a) Ichikawa, E.; Yamamura, S.; Kato, K. *Tetrahedron Lett.* **1999**, *40*, 7285–7388. (b) Kikuchi, Y.; Kurata, H.; Shigeru, N.; Yamamura, S. *Tetrahedron Lett.* **1997**, *38*, 4795–4798. (c) Gumina, G.; Chu, C. K. *Org. Lett.* **2002**, *4*, 1147–1149. (d) Nishiyama, S.; Yamamura, S.; Kato, K.; Takita, T. *Tetrahedron Lett.* **1988**, *29*, 4743–4746.

(1) (a) Tyler, P. C.; Clinch, K. PCT Int. Appl. WO 2005033076, 2005. (b) Karlsson, S.; Hogberg, H.-E. *Tetrahedron: Asymmetry* **2001**, *12*, 1977–1982.




Figure 1. Synthetic potential of key intermediate (*S*)-3-(hydroxymethyl)butane-1,2,4-triol: (A) (aza)sugar derivatives; (B) ceramides and phytoceramides with an inverted amide functionality; (C) PDMP homologues; (D) *N*-(dihydro)homo(phyto)ceramides.

D-threo-PDMP homologues⁴ (*D-threo*-1-phenyl-2-amino decanoyl-3-morpholinopropanol), an inhibitor of glucosyl ceramide synthase which is a potential target in the treatment of cancer.⁵

Here, we wish to demonstrate the usefulness of the (*S*)-3-(hydroxymethyl)butane-1,2,4-triol scaffold in preparing a novel class of homoceramide analogues (Figure 1; D), which contain an additional methylene group between the *N*-acyl chain and C2 (Figure 2; 2–4). Interestingly, our procedure seemed also convenient for the synthesis of *N*-homophytoceramide (5), which can serve as a key intermediate for the synthesis of α -galactosyl-*N*-homoceramide. This latter compound represents a homologue of α -galactosylceramide, a potentially useful agent for the treatment of autoimmune diseases.⁶

Homologation is a classical tool in medicinal chemistry to alter biological properties of endogenous compounds. Salbutamol, for instance, a widely⁷ used bronchodilator with agonistic properties for β_2 -receptors, consists of a 4-hydroxy-3-hydroxymethylphenyl moiety instead of the catechol ring, which is present in (nor)adrenaline.

(4) Abe, A.; Wild, S. R.; Lee, L.; Shayman, J. A. *Curr. Drug Metab.* **2001**, *2*, 331–338.

(5) (a) Radin, N. S. *Bioorg. Med. Chem.* **2003**, *11*, 2123–2142. (b) Reynolds, C. P.; Maurer, B. J.; Kolesnick, R. N. *Cancer Lett.* **2004**, *206*, 169–180.

(6) Representative reviews: (a) Van Kaer, L. *Nat. Immunol.* **2005**, *5*, 31–42. (b) Yamamura, T.; Miyamoto, K.; Illes, Z.; Pal, E.; Araki, M.; Miyake, S. *Curr. Top. Med. Chem.* **2004**, *4*, 561–567.

(7) Salbutamol is the representative for treatment of asthma and chronic obstructive pulmonary disease (COPD) in the WHO Essential Medicines Library (EMLib); <http://mednet3.who.int/EMLib>.





Figure 2. General structures of *O*₁-homoceramides (1) and *N*-(dihydro)homo(phyto)ceramides (2–5).

Recently, our group reported an expedient route for the synthesis of *D-erythro-O*₁-homoceramides⁸ (Figure 2; 1). An alternative synthetic procedure for this class of non-natural ceramide analogues was later proposed by Ogino and co-workers.⁹ The authors found that several representatives exhibited considerable apoptotic activities. Recently, Schmidt and co-workers¹⁰ presented the synthesis of *O*₁-homosphingosine phosphonate starting from *D*-galactose.

Epoxide synthon 6 (Scheme 1), prepared from *D*-isoascorbic acid as previously described,¹¹ provided the stereochem-

Scheme 1. Synthesis of Key Intermediate 8



ical and structural features required for our synthetic approach. Since epoxide opening is often hampered by


(8) De Jonghe, S.; Lamote, I.; Venkataraman, K.; Boldin, S. A.; Hillaert, U.; Rozenski, J.; Hendrix, C.; Busson, R.; De Keukeleire, D.; Van Calenbergh, S.; Futerman, A. H.; Herdewijn, P. *J. Org. Chem.* **2002**, *67*, 988–996.

regioselectivity issues involving the use of hazardous cyanide^{1b} or additional synthetic steps implicated in allylic transformations,^{3b} we opted to use 1,3-dithiane¹² to introduce branching.

Hence, tritylation followed by reduction of the ester and subsequent epoxide opening with 2-lithio-1,3-dithiane¹³ produced intermediate 1,3-diol **7** with complete regioselectivity (47% yield in six steps from D-isoascorbic acid). Protection of 1,3-diol **7** with di-*tert*-butylsilyl ditriflate followed by dithiane deprotection with MeI under alkaline conditions and final reduction of the unmasked aldehyde with NaBH₄ gave access to **8** (75% from **7**, 36% from D-isoascorbic acid in nine steps), which represents a unique intermediate from which each of the primary alcohols can selectively be addressed for further modification.

Access to D-*ribo*-N-homophytoceramide **5** is outlined in Schemes 2 and 3. Mesylation of intermediate **8** followed by

Scheme 2. Synthesis of Azido Intermediate **10**



azide introduction and trityl removal yielded alcohol **9** in good yield (83%). Subsequent periodinane oxidation and addition of tetradecylmagnesium chloride to the thus formed aldehyde furnished protected azido-N-homophytosphingosine **10** (40%) as a single diastereomeric form.

Assignment of the *erythro* configuration was achieved by converting intermediate **10** to the 3,4-isopropylidene-protected triol **11** in a two-step sequence entailing silyl deprotection and dioxolane formation (Scheme 3; 51%) and subsequent comparison of ¹H NMR data with similarly protected natural D-*ribo*-azidophytosphingosine **12**.^{14,15}

Azide reduction under Staudinger conditions following TBDMS protection of the secondary alcohol in **10** and

(9) (a) Shikata, K.; Niiro, H.; Azuma, H.; Tachibana, T.; Ogino, K. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 613–616. (b) Shikata, K.; Niiro, H.; Azuma, H.; Ogino, K.; Tachibana, T. *Bioorg. Med. Chem.* **2003**, *11*, 2723–2728.

(10) Tarnowski, A.; Retz, O.; Bar, T.; Schmidt, R. R. *Eur. J. Org. Chem.* **2005**, *6*, 1129–1141.

(11) (a) Dunigan, J.; Weigel, L. O. *J. Org. Chem.* **1991**, *56*, 6225–2557. (b) Ikunaka, M.; Matsumoto, J.; Fujima, Y.; Hirayama, Y. *Org. Proc. Res. Dev.* **2002**, *6*, 49. (c) Ziegler, F. E.; Belema, M. *J. Org. Chem.* **1994**, *59*, 7962.


(12) For a review on the role of 1,3-dithianes in natural product synthesis, see: Yus, M.; Nájera, C.; Foubelo, F. *Tetrahedron* **2003**, *59*, 6147–6212.

(13) Paquette, L. A.; Boulet, S. L. *Synthesis* **2002**, 888–894.

(14) (a) Compound **12** has been prepared according to literature procedures starting from commercially available D-*ribo*-phytosphingosine (ref 15). (b) Both **11** (³J_{3,4} = 5.57 Hz) and **12** (³J_{3,4} = 5.38 Hz) exhibit a comparable vicinal coupling constant, thereby indicating a *cis*-relationship of the ring substituents (standard sphingolipid numbering is used for clarity reasons).

(15) Schmidt, R. R.; Maier, T. *Carbohydr. Res.* **1998**, *174*, 169–179.


Scheme 3. Synthesis of D-*ribo*-N-Homophytoceramide **5**



subsequent acylation of the primary amine with palmitoyl chloride afforded silyl-protected intermediate **13** (39%). Final desilylation with TBAF furnished D-*ribo*-N-homophytoceramide **5** (62%).

Since the presence of azides in Wittig olefination has led to controversial results,¹⁶ we opted to transform the azide to a phthalimide in a two-step sequence involving reduction of **9** under Staudinger conditions followed by phthalimide protection of the thus formed primary amine, thereby affording intermediate **14** in good yield (Scheme 4; 88%).


Scheme 4. Synthesis of Z-Alkene Intermediate **15**



Subsequent oxidation of the primary alcohol with Dess–Martin periodinane yielded the intermediate aldehyde. Al-

(16) Selected examples: (a) Nugent, T. C.; Hudlicky, T. *J. Org. Chem.* **1998**, *63*, 510–520. (b) Timmer, M. S. M.; Verdoes, M.; Slidregt, L. A. J. M.; van der Marel, G. A.; van Boom, J. H.; Overkleef, H. S. *J. Org. Chem.* **2003**, *68*, 9406–9411. (c) Hudlicky, T.; Nugent, T. *J. Org. Chem.* **1994**, *59*, 7944–7946.

Scheme 5. Access to (Dihydro)-*N*-homoceramides **2–4**



though reaction conditions specifically addressed the *E*-isomer, Schlosser–Wittig olefination surprisingly only produced *Z*-isomer **15**. Hydrazine-mediated phthalimide deprotection followed by acylation with palmitoyl chloride and silyl deprotection with TBAF furnished (*Z*)-*N*-homoceramide **2** (Scheme 5; 59%). Photoinduced double bond isomerization in the presence of diphenyl disulfide as sensitizer produced,

after two recrystallizations, isomerically pure (*E*)-*N*-homoceramide **3** (38%). Finally, hydrogenation of the *Z*-double bond in **2** gave access to dihydro-*N*-homoceramide **4** (84%).

In summary, we have reported an expedient route toward a versatile (*S*)-3-(hydroxymethyl)butane-1,2,4-triol scaffold starting from *D*-isoascorbic acid, a common food preservative. The key transformation in this approach was the introduction of branching through a high yield and fully regioselective 2-lithio-1,3-dithiane epoxide opening. On the basis of this flexible synthon, we report the first synthesis of (dihydro)-*N*-homoceramides **2–4**. In addition, a fully stereoselective Grignard reaction gave access to *D-ribo-N*-homophytoceramide **5**, which will be utilized in a further study toward the elaboration of its α -galactosyl derivative.

Acknowledgment. We wish to thank S. Goormans for kindly providing a sample of compound **12**. S.V.C. is indebted to the “Fonds voor Wetenschappelijk Onderzoek-Vlaanderen” for financial support (“krediet aan navorser”).

Supporting Information Available: Full experimental details and copies of ¹H and ¹³C spectra are available. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL052335X